Dengue Tetravalent Vaccine

Aedes aegypti mosquito

About Dengue
Dengue infects up to 100 million people each year leading to widespread dengue fever and over 250,000 cases of more serious and potentially fatal dengue hemorrhagic fever/dengue shock syndrom (DHF/DSS). The virus is primarily transmitted by the bite of infected mosquitos; specifically an invasive tropical/subtropical species that originated in Africa and has spread worldwide. According to the WHO, dengue ranks as the most important mosquito borne viral disease in the world with 40% of the world population living in areas where there is a risk of dengue transmission. See this interactive map that shows the countries of the world at high risk of dengue infection.

A tetravalent vaccine for dengue
There is no vaccine for preventing dengue. Altravax is developing a singular molecular vaccine, which builds from candidates that completed preclinical evaluations. The Altravax vaccine candidate is predicted to improve compliance and reduce risk from multiple dengue infections. The most advanced competing product currently under clinical evaluation is virus based, has an extended dose regimen (3 doses over a year), stability challenges and risk of dengue infection prior to final dose.

A major challenge for developing a dengue vaccine is that there are four related dengue viruses (DENV 1, DENV 2, DENV 3, and DENV 4). Infection by one strain, while typically not life-threatening, may increase the risk that a subsequent infection from another strain can lead to serious or potentially fatal illness (DHF/DSS). It is therefore critical that a vaccine protect against all four strains simultaneously.

Development Status
Altravax’s dengue vaccine candidate is based on a VLP platform and has completed R&D and demonstrated immunogenicity in non-human primates.